Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
Blood|April 20, 2021
Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCLAnja Schmitt, Wendan Xu, Philip Bucher, et al.
International Journal of Cancer|June 15, 2017
TP53 mutation and survival in aggressive B cell lymphomaThorsten Zenz, Markus Kreuz, Maxi Fuge, et al.
Leukemia|January 5, 2023
Molecular profiling of EBV associated diffuse large B-cell lymphomaFabian Frontzek, Annette M Staiger, Ramona Wullenkord, et al.
Hemasphere|March 10, 2025
Age- and gender-specific molecular characteristics of diffuse large B-cell lymphoma: Results from clinical trials of the DSHNHL/GLAKatrin S Kurz, Sophia Steinlein, Markus Kreuz, et al.
Blood|October 1, 2011
MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotypeEllen Leich, Alberto Zamo, Heike Horn, et al.
Blood|November 8, 2019
Localized- and advanced-stage follicular lymphomas differ in their gene expression profilesAnnette M Staiger, Eva Hoster, Vindi Jurinovic, et al.
Blood|December 21, 2018
The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphomaRabea Wagener, Julian Seufert, Francesco Raimondi, et al.
Blood|February 25, 2018
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphologyDavid W Scott, Rebecca L King, Annette M Staiger, et al.
Blood|July 16, 2016
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapyVindi Jurinovic, Robert Kridel, Annette M Staiger, et al.
Pageof 6